Vanta Bioscience Limited has announced a key leadership appointment, naming Ms. Pooja Kothari as the company's new Company Secretary and Compliance Officer. The appointment was formally approved by the Board of Directors during their meeting held on January 30, 2026, and takes effect immediately from the same date.

Board Meeting Details

The Board of Directors convened on Friday, January 30, 2026, to deliberate on the appointment. The meeting commenced at 6:30 P.M. and concluded at 7:00 P.M. The appointment was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointee Profile and Qualifications

Ms. Kothari brings substantial expertise to her new role, having worked extensively with private and unlisted public companies. Her professional experience spans 4 years, during which she has developed comprehensive knowledge in Company Law and Secretarial Compliances.

Appointment Terms and Compliance

The appointment has been structured according to terms and conditions recommended by the Nomination and Remuneration Committee (NRC) and subsequently approved by the Board. Key compliance aspects of the appointment include:

• Ms. Kothari has no associations with any Directors or Key Managerial Personnel of the company
• She has not been debarred from holding office by any regulatory authority
• The appointment complies with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Regulatory Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Regulations by informing BSE Limited about this appointment. The notification was signed by Venkata Sathya Murali Dokka, Chief Financial Officer of Vanta Bioscience Limited, ensuring proper corporate governance protocols were followed.

This appointment strengthens the company's compliance framework and demonstrates its commitment to maintaining robust corporate governance standards. Ms. Kothari's expertise in secretarial compliances will be instrumental in ensuring the company meets all regulatory requirements effectively.

Vanta Bioscience Limited, a Hyderabad-based company, is facing legal challenges as an application has been filed against it under Section 9 of the Insolvency and Bankruptcy Code, 2016. The application was submitted to the National Company Law Tribunal (NCLT), Hyderabad Bench, by S Venkata Rao, a former executive of the company.

Details of the Application

S Venkata Rao, who resigned from his position as Whole Time Director & CEO of Vanta Bioscience on January 04, 2021, has alleged that the company defaulted on salary payments and interest, amounting to a total of Rs. 1.18 crore. Based on these claims, Rao is seeking the initiation of a Corporate Insolvency Resolution Process (CIRP) against the company.

Company's Response

Vanta Bioscience has taken a firm stance against these allegations. The company has:

• Denied all allegations and claims made by S Venkata Rao
• Labeled the claims as baseless
• Sent an appropriate reply to the concerned authorities
• Sought legal advice to protect its interests
• Stated that it has not received any other communications from NCLT regarding this matter

Implications and Next Steps

The filing of this application under the Insolvency and Bankruptcy Code could have significant implications for Vanta Bioscience if the NCLT decides to admit the case. However, at this stage, the company appears to be taking proactive steps to address the situation.

Investors and stakeholders of Vanta Bioscience will likely be watching closely as this legal matter unfolds. The outcome of this case could potentially impact the company's financial standing and operations.

As the situation develops, more information may become available regarding the merits of the case and any potential resolutions between Vanta Bioscience and its former executive.